Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports (Link under the title) TOSHIO INUI1,2,3⇑, KENTARO KUBO2, DAISUKE KUCHIIKE1,2 YOSHIHIRO UTO1, TAKAHITO NISHIKATA4, NORIHIRO SAKAMOTO5 and MARTIN METTE3⇑ + Author Affiliations: 1Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan 2Saisei Mirai Cell Processing Center, Osaka, Japan 3Inui Immunotherapy Clinic, Osaka, Japan 4Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe, Japan 5Division of Food and Drug Evaluation Science, Department of Community Medicine and Social Healthcare Science, Graduate School of Medicine, Kobe University, Kobe, Japan Correspondence to: Dr. Toshio Inui and Mr. Martin Mette, Inui Cancer Immunotherapy Clinic, 6-14-17 Kindacho, Moriguchi-shi, 570-0011, Japan. Tel/Fax: +81 669025251, e-mail: email@example.com Abstract Background: Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy. Results: Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects. Conclusion: We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases.